On a scale of 0 to 100, Biomerica holds a
performance score of 6. The firm shows a Beta (market volatility) of 0.2004, which signifies not very significant fluctuations relative to the market. Let's try to break down what Biomerica's beta means in this case. As returns on the market increase, Biomerica returns are expected to increase less than the market. However, during the bear market, the loss on holding Biomerica will be expected to be smaller as well. Although it is vital to follow
Biomerica historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing
future performance of any stock is to evaluate the business as a whole together with its past performance, including all
available fundamental and
technical indicators. We have found twenty-one
technical indicators for Biomerica, which you can use to evaluate the performance of the firm. Please makes use of Biomerica
maximum drawdown, and the
relationship between the
information ratio and
downside variance to make a quick decision on whether Biomerica
price patterns will revert.
The successful prediction of Biomerica
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Biomerica, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Biomerica based on Biomerica hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Biomerica's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Biomerica's related companies.
Watch out for price decline
Please consider monitoring Biomerica on a daily basis if you are holding a position in it. Biomerica is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Biomerica stock to be traded above the $1 level to remain listed. If Biomerica stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Biomerica expected Price
Biomerica technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Biomerica technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Biomerica trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Biomerica Gross Profit
Biomerica Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Biomerica previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Biomerica Gross Profit growth over the last 10 years. Please check Biomerica's
gross profit and other
fundamental indicators for more details.
A Deeper Perspective
The current price rise of Biomerica could raise concerns from investors as the firm closed today at a share price of
5.86 on very low momentum in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
October. The stock standard deviation of daily returns for 30 days investing horizon is currently 7.54. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biomerica partners.
| 2017 | 2018 | 2019 | 2020 (projected) |
Book Value per Share | 0.51 | 0.43 | 1.4 | 1.16 | Asset Turnover | 1.13 | 1.01 | 0.68 | 0.75 |
Cost of Revenue Breakdown
Biomerica Cost of Revenue is increasing over the years with slightly volatile fluctuation. Cost of Revenue is expected to dwindle to about 4.8
M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Biomerica Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 4.91 Million
| 2013 | 3.45 Million |
| 2014 | 3.42 Million |
| 2015 | 3.62 Million |
| 2016 | 3.77 Million |
| 2017 | 3.81 Million |
| 2018 | 3.91 Million |
| 2019 | 4.91 Million |
| 2020 | 4.82 Million |
Can Biomerica build up on the current rise?
Current variance is at 56.32. Biomerica is displaying above-average volatility over the selected time horizon. Investors should scrutinize Biomerica independently to ensure intended market timing strategies are aligned with expectations about Biomerica volatility.
Our Conclusion on Biomerica
Whereas other entities within the diagnostics & research industry are still a little expensive, even after the recent corrections, Biomerica may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Biomerica nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biomerica.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Biomerica. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
